Iovance [IOVA] vs Regeneron [REGN] Detailed Stock Comparison

Iovance Biotherapeutics, Inc.

NASDAQ
Loading...

Regeneron Pharmaceuticals, Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Iovance Biotherapeutics, Inc. wins in 5 metrics, Regeneron Pharmaceuticals, Inc. wins in 14 metrics, with 0 ties. Regeneron Pharmaceuticals, Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Iovance Biotherapeutics, Inc. Regeneron Pharmaceuticals, Inc. Better
P/E Ratio (TTM) -3.19 18.00 Regeneron Pharmaceuticals, Inc.
Price-to-Book Ratio 2.18 2.45 Iovance Biotherapeutics, Inc.
Debt-to-Equity Ratio 7.08 9.51 Iovance Biotherapeutics, Inc.
PEG Ratio 0.10 -4.80 Iovance Biotherapeutics, Inc.
EV/EBITDA -3.52 16.72 Regeneron Pharmaceuticals, Inc.
Profit Margin (TTM) -148.38% 31.41% Regeneron Pharmaceuticals, Inc.
Operating Margin (TTM) -84.66% 23.13% Regeneron Pharmaceuticals, Inc.
EBITDA Margin (TTM) N/A 23.13% N/A
Return on Equity -55.50% 14.86% Regeneron Pharmaceuticals, Inc.
Return on Assets (TTM) -27.30% 5.91% Regeneron Pharmaceuticals, Inc.
Free Cash Flow (TTM) $-336.24M $3.77B Regeneron Pharmaceuticals, Inc.
Dividend Yield N/A 0.59% N/A
1-Year Return 82.14% 15.66% Iovance Biotherapeutics, Inc.
Price-to-Sales Ratio (TTM) 5.78 5.50 Regeneron Pharmaceuticals, Inc.
Enterprise Value $1.28B $70.98B Regeneron Pharmaceuticals, Inc.
EV/Revenue Ratio 4.85 4.95 Iovance Biotherapeutics, Inc.
Gross Profit Margin (TTM) 50.32% 84.95% Regeneron Pharmaceuticals, Inc.
Revenue per Share (TTM) $1 $137 Regeneron Pharmaceuticals, Inc.
Earnings per Share (Diluted) $-1.09 $41.48 Regeneron Pharmaceuticals, Inc.
Beta (Stock Volatility) 0.76 0.40 Regeneron Pharmaceuticals, Inc.
Short % of Float 28.94% 2.55% Regeneron Pharmaceuticals, Inc.

Iovance Biotherapeutics, Inc. vs Regeneron Pharmaceuticals, Inc. Stock Performance Analysis

Loading Price Chart...

IOVA
REGN

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Iovance Biotherapeutics, Inc.-1.23%0.75%16.81%-0.25%86.57%59.92%
Regeneron Pharmaceuticals, Inc.0.46%0.60%-11.93%-18.75%-18.29%-20.78%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Iovance Biotherapeutics, Inc.82.14%-49.75%-83.54%-45.74%-96.74%-96.29%
Regeneron Pharmaceuticals, Inc.15.66%-21.83%13.80%72.82%1,033.17%4,804.97%

Performance & Financial Health Analysis: Iovance Biotherapeutics, Inc. vs Regeneron Pharmaceuticals, Inc.

MetricIOVAREGN
Market Information
Market Cap i$1.43B$80.98B
Market Cap CategorySmall capLarge cap
10 Day Avg. Volume i17,329,416642,495
90 Day Avg. Volume i14,583,335617,765
Last Close$4.03$614.98
52 Week Range$1.66 - $5.63$503.25 - $821.11
% from 52W High-28.42%-25.10%
All-Time High$165.00 (Jun 06, 2011)$1,211.20 (Aug 26, 2024)
% from All-Time High-97.56%-49.23%
Growth Metrics
Quarterly Revenue Growth0.18%0.03%
Quarterly Earnings Growth0.18%-0.08%
Financial Health
Profit Margin (TTM) i-1.48%0.31%
Operating Margin (TTM) i-0.85%0.23%
Return on Equity (TTM) i-0.56%0.15%
Debt to Equity (MRQ) i7.089.51
Cash & Liquidity
Book Value per Share (MRQ)$1.70$304.65
Cash per Share (MRQ)$0.72$83.86
Operating Cash Flow (TTM) i$-302,408,000$4.98B
Levered Free Cash Flow (TTM) i$-162,422,128$3.26B
Dividends
Last 12-Month Dividend Yield iN/A0.59%
Last 12-Month Dividend iN/A$4.46

Valuation & Enterprise Metrics Analysis: Iovance Biotherapeutics, Inc. vs Regeneron Pharmaceuticals, Inc.

MetricIOVA (Apr 24, 2026)REGN (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i-3.1918.00
Forward P/E i-15.6314.21
PEG Ratio i0.10-4.80
Price to Sales (TTM) i5.785.50
Price to Book (MRQ) i2.182.45
Market Capitalization
Market Capitalization i$1.43B$80.98B
Enterprise Value i$1.28B$70.98B
Enterprise Value Metrics
Enterprise to Revenue i4.854.95
Enterprise to EBITDA i-3.5216.72
Risk & Other Metrics
Beta i0.760.40
Book Value per Share (MRQ) i$1.70$304.65

Financial Statements Comparison: Iovance Biotherapeutics, Inc. vs Regeneron Pharmaceuticals, Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricIOVA (2025)REGN (2025)
Revenue/Sales i263.50M14.34B
Cost of Goods Sold i173.18M2.10B
COGS % of Revenue i65.7%14.6%
Gross Profit i90.32M12.24B
Gross Margin i34.3%85.4%
Research & Development i300.27M5.85B
Operating Income (EBIT) i-398.21M3.70B
Operating Margin i-151.1%25.8%
EBITDA i-345.75M5.00B
EBITDA Margin i-131.2%34.8%
Pre-Tax Income i-393.05M5.23B
Pre-Tax Income % of Revenue i-149.2%36.5%
Income Tax i-2.07M725.80M
Income Tax % of Revenue i-0.8%5.1%
Net Income (Profit) i-390.98M4.50B
Profit Margin i-148.4%31.4%

Balance Sheet & Liquidity Metrics

MetricIOVA (2025)REGN (2025)
Cash & Equivalents i163.08M3.12B
Total Current Assets i442.69M18.02B
Total Current Assets % of Revenue i168.0%125.7%
Total Current Liabilities i138.36M4.37B
Total Current Liabilities % of Revenue i52.5%30.5%
Long-Term Debt i44.40M2.71B
Long-Term Debt % of Revenue i16.9%18.9%
Total Shareholders Equity i698.58M31.26B
Retained Earnings i-2.78B35.80B
Retained Earnings % of Revenue i-1,053.3%249.6%
Property, Plant & Equipment i84.70M1.54B

Cash Flow Statement Comparison

MetricIOVA (2025)REGN (2025)
Operating Cash Flow i-329.03M6.30B
Operating Cash Flow % of Revenue i-124.9%43.9%
Capital Expenditures i-33.84M0
Free Cash Flow i-336.24M3.77B
FCF Margin i-127.6%26.3%
Debt Repayment iN/AN/A
Common Stock Repurchase iN/A-3.97B

Short Interest & Institutional Ownership Analysis

MetricIOVAREGN
Shares Short i110.83M2.55M
Short Ratio i6.524.46
Short % of Float i28.94%2.55%
Shares Outstanding i411.94M105.72M
Float Shares i353.45M98.55M
% Held by Insiders i0.40%1.98%
% Held by Institutions i71.15%91.08%
% Held by Public i28.45%6.94%

Dividend Analysis & Yield Comparison: Iovance Biotherapeutics, Inc. vs Regeneron Pharmaceuticals, Inc.

MetricIOVAREGN
Last 12-Month Dividend iN/A$4.46
Last 12-Month Dividend Yield iN/A0.59%
3-Year Avg Annual Dividend iN/A$1.49
3-Year Avg Dividend Yield iN/A0.13%
3-Year Total Dividends iN/A$4.46
Ex-Dividend DateN/AFeb 20, 2026